Black Diamond Therapeutics, Inc. (BDTX)

6.11 -0.64 (-9.48%) 收市：04:00PM EDT

Black Diamond Therapeutics, Inc.

One Main Street
14th Floor
Cambridge, MA 02142
United States
617 252 0848
https://www.blackdiamondtherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 54

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Mark A. Velleca M.D., Ph.D.	CEO, President & Chairman	795.98k	無	1964
Dr. David M. Epstein Ph.D.	Co-Founder & Director	969.69k	無	1959
Dr. Fang Ni Pharm.D.	CFO, Principal Financial Officer and Chief Business Officer	665.98k	無	1987
Dr. Sergey Yurasov M.D., Ph.D.	Chief Medical Officer	718.92k	無	1969
Dr. Elizabeth Buck Ph.D.	Co-Founder & Chief Scientific Officer	340.47k	無	1975
Mr. Brent Hatzis-Schoch Esq., J.D.	COO & General Counsel	683.29k	無	1965
Ms. Elizabeth L. Montgomery	Chief People Officer	無	無	1972
Ms. Melanie Morrison	Chief Development Officer	無	無	1975
Ms. Erika Jones	Senior VP of Finance & Corporate Controller	無	無	1985

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

公司管治

截至 2024年5月1日 止，Black Diamond Therapeutics, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：8；董事會：10；股東權利：8；現金賠償：7。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。